Incyte and MorphoSys Report First Patient Dosing in P-III frontMIND Study of Tafasitamab + Lenalidomide as a 1L Treatment for DLBCL

May 12, 2021 Auto Bot Clinical Trials, diffuse large B-cell lymphoma, Incyte, MorphoSys, P-III, tafasitamab 0

Shots:

  • The first patient has been dosed in the P-III frontMIND study evaluating tafasitamab + lenalidomide + R-CHOP vs R-CHOP alone as a 1L treatment for high-intermediate and high-risk ~880 patients with DLBCL
  • The 1EP of the study is PFS and 2EP include event-free survival, OS, metabolic CRR, and ORR
  • The preliminary data from the ongoing P-Ib firstMIND study showed a 91.1% response rate across both arms in a patient population, and combination therapy showed a tolerable profile. The results will further support the frontMIND study for the combination therapy

Click here to­ read full press release/ article | Ref: Business Wire | Image: Business Wire

The post Incyte and MorphoSys Report First Patient Dosing in P-III frontMIND Study of Tafasitamab + Lenalidomide as a 1L Treatment for DLBCL first appeared on PharmaShots.